Literature DB >> 32311402

Highly efficient Pyrococcus furiosus recombinant L-asparaginase with no glutaminase activity: Expression, purification, functional characterization, and cytotoxicity on THP-1, A549 and Caco-2 cell lines.

Hesham Saeed1, Asmaa Hemida2, Nefertiti El-Nikhely2, Manal Abdel-Fattah2, Manal Shalaby3, Ahmed Hussein2, Ahmad Eldoksh2, Farid Ataya4, Nihal Aly5, Nikolaos Labrou6, Hisham Nematalla7.   

Abstract

L-Asparaginase (L-ASNase EC 3.5.1.1) is considered as an important biopharmaceutical drug enzyme in the treatment of childhood acute lymphoblastic leukemia (ALL). In the present study, Pyrococcus furiosus L-ASNase gene was cloned into pET26b (+), expressed in E. coli BL21(DE3) pLysS, and purified to homogeneity using Ni2+ chelated Fast Flow Sepharose resin with 5.7 purification fold and 23.9% recovery. The purified enzyme exhibited a molecular weight of ~33,660 Da on SDS-PAGE and showed maximal activity at 50 °C and pH 8.0. It retained 98.3% and 60.7% initial activity after 60 min at 37 °C and 50 °C, respectively. The recombinant enzyme showed highest substrate specificity towards L-ASNase substrate, while no detectable specificity was observed for l-glutamine, urea, and acrylamide at 10 mM concentration. The Km and Vmax of the purified recombinant enzyme as calculated using Lineweaver-Burk plot were determined to be 1.623 mM and 105 μmol min-1 mg-1, respectively. Human leukemia cell line THP-1 treated with recombinant L-ASNase showed significant morphological changes, and the IC50 of the purified enzyme was found to be 0.8 IU. Moreover, the purified recombinant L-ASNase induced cytotoxic effects on lung adenocarcinoma A549 and colorectal adenocarcinoma Caco-2 cell lines with IC50 of 1.78 IU and 30 IU, respectively.
Copyright © 2020 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Acute lymphoblastic leukemia, expression; Cloning; Cytotoxicity; L-Asparaginase; Pyrococcus furiosus

Mesh:

Substances:

Year:  2020        PMID: 32311402     DOI: 10.1016/j.ijbiomac.2020.04.080

Source DB:  PubMed          Journal:  Int J Biol Macromol        ISSN: 0141-8130            Impact factor:   6.953


  7 in total

Review 1.  Bio-prospecting the future in perspective of amidohydrolase L-glutaminase from marine habitats.

Authors:  Nidhi Y Patel; Dhritiksha M Baria; Shivani M Yagnik; Kiransinh N Rajput; Rakesh R Panchal; Vikram H Raval
Journal:  Appl Microbiol Biotechnol       Date:  2021-07-08       Impact factor: 4.813

2.  Molecular cloning, characterization, and in-silico analysis of l-asparaginase from Himalayan Pseudomonas sp. PCH44.

Authors:  Subhash Kumar; Sanyukta Darnal; Vijeta Patial; Virender Kumar; Vijay Kumar; Sanjay Kumar; Dharam Singh
Journal:  3 Biotech       Date:  2022-07-09       Impact factor: 2.893

3.  Bacillus sonorensis L. Asparaginase: Cloning, Expression in E. coli and Characterization.

Authors:  Nihal Aly; Amani El-Ahwany; Farid Shokry Ataya; Hesham Saeed
Journal:  Protein J       Date:  2020-10-26       Impact factor: 2.371

4.  Metagenomic discovery and functional validation of L-asparaginases with anti-leukemic effect from the Caspian Sea.

Authors:  Motahareh Sobat; Sedigheh Asad; Mahboubeh Kabiri; Maliheh Mehrshad
Journal:  iScience       Date:  2021-01-05

5.  Development of Escherichia coli asparaginase II for the Treatment of Acute Lymphocytic Leukemia: In Silico Reduction of asparaginase II Side Effects by a Novel Mutant (V27F).

Authors:  Noeman Ardalan; Abbas Akhavan Sepahi; Ramazan Ali Khavari-Nejad
Journal:  Asian Pac J Cancer Prev       Date:  2021-04-01

Review 6.  Structural and biophysical aspects of l-asparaginases: a growing family with amazing diversity.

Authors:  Joanna I Loch; Mariusz Jaskolski
Journal:  IUCrJ       Date:  2021-06-30       Impact factor: 4.769

Review 7.  Molecular Analysis of L-Asparaginases for Clarification of the Mechanism of Action and Optimization of Pharmacological Functions.

Authors:  Marina V Pokrovskaya; Vadim S Pokrovsky; Svetlana S Aleksandrova; Nikolay N Sokolov; Dmitry D Zhdanov
Journal:  Pharmaceutics       Date:  2022-03-09       Impact factor: 6.321

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.